Drug Profile

CEP 2563

Alternative Names: CEP-2563; KT-8391

Latest Information Update: 26 Oct 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cephalon
Class Antineoplastics
Mechanism of Action Protein tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

28 Jun 2002 No development reported - Phase-I for Solid tumours in USA (IV-infusion)
31 Dec 2001 Schwarz Pharma has terminated its licence for CEP 2563
13 Jan 2000 Schwarz Pharma has licensed rights to CEP 2563 in markets other than the US, Asia and Japan

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com